Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 25

Showing 25 citing articles:

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 43
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 28
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access | Times Cited: 1
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 6
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 14
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 844-844
Open Access | Times Cited: 5
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 5
AI-driven covalent drug design strategies targeting main protease (m pro ) against SARS-CoV-2: structural insights and molecular mechanisms
Mohammad Hossein Haghir Ebrahim Abadi, Abdulrahman Ghasemlou, Fatemeh Bayani, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-29
Closed Access | Times Cited: 4
In Silico Discovery of SARS-CoV-2 Main Protease Inhibitors Using Docking, Molecular Dynamics, and Fragment Molecular Orbital Calculations
Takeshi Ishikawa, Kenji Matsumoto, Toshiyuki Hamada, et al.
The Journal of Physical Chemistry B (2025) Vol. 129, Iss. 6, pp. 1740-1749
Closed Access
The Dynamical Asymmetry in SARS-CoV2 Protease Reveals the Exchange Between Catalytic Activity and Stability in Homodimers
Velia Minicozzi, Alessandro Giuliani, Giampiero Mei, et al.
Molecules (2025) Vol. 30, Iss. 7, pp. 1412-1412
Open Access
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 10
Computer Aided Structure-Based Drug Design of Novel SARS-CoV-2 Main Protease Inhibitors: Molecular Docking and Molecular Dynamics Study
Dmitry S. Kolybalov, E. D. Kadtsyn, Sergey G. Arkhipov
Computation (2024) Vol. 12, Iss. 1, pp. 18-18
Open Access | Times Cited: 2
3-Chymotrypsin-like Protease (3CLpro): Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials
Vitor Martins de Freitas Amorim, Eduardo Pereira Soares, Anielle Salviano de Almeida Ferrari, et al.
(2024)
Open Access | Times Cited: 2
Identification of a novel inhibitor of SARS‐CoV‐2 main protease: an in silico, biochemical, and cell‐based approach
Aditya Trivedi, Vandana Kardam, Krishna Kishore Inampudi, et al.
FEBS Journal (2023) Vol. 290, Iss. 23, pp. 5496-5513
Closed Access | Times Cited: 4
Mechanistic Insights into the Mutational Landscape of the Main Protease/3CLPro and Its Impact on Long-Term COVID-19/SARS-CoV-2 Management
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonjabulo Ntombikhona Magwaza, et al.
(2024)
Open Access | Times Cited: 1
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Marcel Arruda Diogo, Augusto Gomes Teixeira Cabral, Renata Barbosa de Oliveira
Pathogens (2024) Vol. 13, Iss. 10, pp. 825-825
Open Access | Times Cited: 1
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Palaniyandi Muthukutty, Jaime MacDonald, So Young Yoo
Vaccines (2024) Vol. 12, Iss. 11, pp. 1220-1220
Open Access | Times Cited: 1
Natural Products from Marine Actinomycete Genus Salinispora Might Inhibit 3CLpro and PLpro Proteins of SARS-CoV-2: An In Silico Evidence
Omkar Pokharkar, Grigory V. Zyryanov, Mikhail V. Tsurkan
Microbiology Research (2023) Vol. 14, Iss. 4, pp. 1907-1941
Open Access | Times Cited: 3
In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2
Calvin R. Wei, Godwin C. Lang’at
(2023)
Open Access | Times Cited: 2
Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors
Martynas Bagdonas, Kamilė Čerepenkaitė, Aurelija Mickevičiūtė, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13491-13491
Open Access | Times Cited: 2
Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease
Jenson R. Feys, Kyle C. Edwards, Michael Joyce, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 2046-2052
Closed Access
Assessment of optimized FRET substrates as universal corona- and picornavirus main protease substrates for screening assays
Conrad Fischer, Tayla J. Van Oers, Marco J. van Belkum, et al.
RSC Advances (2024) Vol. 14, Iss. 48, pp. 35438-35446
Open Access
Mechanistic Insights into the Mutational Landscape of the Main Protease/3CLPro and Its Impact on Long-Term COVID-19/SARS-CoV-2 Management
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonjabulo Ntombikhona Magwaza, et al.
Future Pharmacology (2024) Vol. 4, Iss. 4, pp. 825-852
Open Access
Discovery of pyrimidoindol and benzylpyrrolyl inhibitors targeting SARS-CoV-2 main protease (Mpro) through pharmacophore modelling, covalent docking, and biological evaluation
Radwa E. Mahgoub, Feda E. Mohamed, Bassam R. Ali, et al.
Journal of Molecular Graphics and Modelling (2023) Vol. 127, pp. 108672-108672
Closed Access | Times Cited: 1
Molecular dynamic simulations to explore the broad-spectrum activity of the inhibitor PF-07321332 against human coronavirus
Meng-Ting Liu, Yuting Wang, Yi Li, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-14
Open Access
Page 1

Scroll to top